Literature DB >> 2324554

Interleukin 6 and its receptor in the immune response and hematopoiesis.

T Hirano1, T Taga, T Matsuda, M Hibi, S Suematsu, B Tang, M Murakami, T Kishimoto.   

Abstract

Interleukin 6 (IL-6) plays critical roles in the immune response and hematopoiesis. It is a potent B cell differentiation factor inducing antibody-forming plasma cells. It enhances interleukin 3-induced proliferation of hematopoietic stem cells. Furthermore, IL-6 induces maturation of megakaryocytes. In IL-6 transgenic mice, a massive polyclonal plasmacytosis and an increase in the number of mature megakaryocytes in the bone marrow were observed. The data indicated that deregulated expression of the IL-6 gene induced a polyclonal plasmacytosis and could be involved in the oncogenesis of plasma cell neoplasias. IL-6 receptor (IL-6R) was molecularly cloned and found to be an immunoglobulin superfamily having an MW of 80 kDa. Upon the binding of IL-6 to its 80 kDa IL-6R, a second non-binding molecule, gp130 was shown to associate with IL-6R. The complex of IL-6 and soluble IL-6R lacking both transmembrane and cytoplasmic domains could bind gp130 and transduce the signal. The results indicate that the IL-6R system consists of two polypeptide chains: one is an 80 kDa ligand-binding molecule and the other is a possible signal transducer, gp130.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2324554     DOI: 10.1002/stem.5530080714

Source DB:  PubMed          Journal:  Int J Cell Cloning        ISSN: 0737-1454


  8 in total

Review 1.  The Impact of Mesenchymal Stem Cells on Differentiation of Hematopoietic Stem Cells.

Authors:  Mahshid Saleh; Karim Shamsasanjan; Aliakbar Movassaghpourakbari; Parvin Akbarzadehlaleh; Zahra Molaeipour
Journal:  Adv Pharm Bull       Date:  2015-09-19

2.  Construction and characterization of a replication-deficient adenovirus expressing rat-soluble interleukin-6 receptor.

Authors:  V Thibault; B Terlain; F L Graham; J Gauldie
Journal:  Mol Med       Date:  1997-08       Impact factor: 6.354

Review 3.  Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy.

Authors:  Aarat M Patel; Larry W Moreland
Journal:  Drug Des Devel Ther       Date:  2010-10-01       Impact factor: 4.162

4.  PLASMA INTERLEUKIN-6 LEVELS MAY BE ASSOCIATED WITH THE LENGTH OF STAY TIME OF ADULT HYPERGLYCEMIC PATIENTS IN AN INTENSIVE CARE UNIT.

Authors:  E Uysal; Y A Acar; R Celik; N Nasuhbeyoglu
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Jul-Sep       Impact factor: 0.877

5.  Crystal structure of interleukin-6 in complex with a modified nucleic acid ligand.

Authors:  Amy D Gelinas; Douglas R Davies; Thomas E Edwards; John C Rohloff; Jeffrey D Carter; Chi Zhang; Shashi Gupta; Yuichi Ishikawa; Masao Hirota; Yuichiro Nakaishi; Thale C Jarvis; Nebojsa Janjic
Journal:  J Biol Chem       Date:  2014-01-12       Impact factor: 5.157

6.  Association between interleukin 6 -174 G/C promoter gene polymorphism and runners' responses to the dietary ingestion of antioxidant supplementation based on pequi (Caryocar brasiliense Camb.) oil: a before-after study.

Authors:  Ana Luisa Miranda-Vilela; Ieler Ferreira Ribeiro; Cesar Koppe Grisolia
Journal:  Genet Mol Biol       Date:  2016-10-10       Impact factor: 1.771

7.  Cardiotrophin-Like Cytokine Factor 1 Exhibits a Myeloid-Biased Hematopoietic-Stimulating Function.

Authors:  Sarah Pasquin; Aurélie Tormo; Jessica Moreau; Véronique Laplante; Mukut Sharma; Jean-François Gauchat; Moutih Rafei
Journal:  Front Immunol       Date:  2019-09-10       Impact factor: 7.561

8.  Paravertebral block can attenuate cytokine response when it replaces general anesthesia for cancer breast surgeries.

Authors:  Sherif S Sultan
Journal:  Saudi J Anaesth       Date:  2013-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.